Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 3/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.41 |
| ▸ | ESRRB | O95718 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6341293 | 0.89 | ACHE (0.46) | ESRRGMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL1027884 | 0.86 | MEN1 (0.47) | MEN1KMT2AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL1935310 | 0.86 | MEN1 (0.47) | ESRRGMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL2881402 | 0.86 | PPARA (0.49) | ESRRGMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL21247482 | 0.86 | KMT2A (0.63) | MEN1KMT2AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL1845384 | 0.85 | MEN1 (0.46) | ESRRGMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL21997106 | 0.85 | KMT2A (0.46) | MEN1KMT2AHTTL3MBTL1BLM | |
| SCHEMBL11898599 | 0.85 | MEN1 (0.46) | ESRRGMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL2575721 | 0.85 | TAAR1 (0.50) | MEN1KMT2AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL1935745 | 0.85 | MEN1 (0.46) | ESRRGMEN1KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082819-B1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-9518050-B2 | Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity | ALMIRALL, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| US-7612084-B2 | Amine derivatives for the treatment of asthma and COPD | PFIZER INC (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| US-6437146-B1 | MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| EP-0445796-B1 | Derivatives of acetic acid containing peptide bonds | HOFFMANN LA ROCHE (CH) | 1998-06-17 | — | — | EP | disclosed |
| WO-1997034905-A1 | PHOSPHORUS CONTAINING ARYLOXY AND ARYLTHIOPROPANOL AMINE DERIVATIVES USEFUL AS BETA ADRENORECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-09-25 | — | — | WO | disclosed |
| WO-1993010074-A1 | ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS BETA-3-ADRENOCEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-05-27 | — | — | WO | disclosed |
| EP-0445796-A2 | Derivatives of acetic acid | F. HOFFMANN-LA ROCHE AG (CH) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265303-A1 | Amine derivatives | HNMT, HRH4, CMA1 | ESRRG 2905/4885MEN1 825/4885KMT2A 1044/4885 |
| US-20090253739-A1 | Amine Derivatives | HNMT, HRH4, CMA1 | ESRRG 2905/4885MEN1 825/4885KMT2A 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.